Search Press releases Keywords From To 30 Sep 2024 UCB announces a head-to-head study evaluating BIMZELX[®]▼(bimekizumab) versus SKYRIZI® (risankizumab) in active psoriatic arthritis Read More 27 Sep 2024 Transparency notification BlackRock, Inc. Read More 27 Sep 2024 UCB announces late-breaking two-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe hidradenitis suppurativa at EADV 2024 Read More 26 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 UCB presents new 4-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe plaque psoriasis at EADV 2024 Read More Pagination First page Previous page Previous … Page 9 Page 10 Page 11 Page 12 Current page 13 Page 14 Page 15 Page 16 Page 17 … Page 13 of 59 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
